Hipertensión arterial por estenosis de la arteria renal en una mujer embarazada. Reporte de un caso

Salud en Tabasco 01/2006;
Source: DOAJ

ABSTRACT Presentamos el caso de una mujer de 24 años de edad, con antecedentes de hipertensión arterial de 2 años de evolución, embarazo de 37 semanas de gestación, la cual ingresó a la unidad de terapia intensiva con datos de edema agudo pulmonar, edema generalizado, e insuficiencia renal. Requirió de ventilación mecánica, uso de inotrópicos, diuréticos, posteriormente se interrumpió el embarazo por cesárea, en los días siguientes mejoró, se inició el protocolo de estudios para determinar la causa de la hipertensión arterial, se demostró estenosis a nivel del ostium de la arteria renal izquierda, se realizó angioplastía con balón. En el presente caso se discuten las causas de la hipertensión por estenosis de la arteria renal, los estudios para el diagnóstico y el tratamiento.

  • Source
    Heart (British Cardiac Society) 09/2002; 88(2):193-7. DOI:10.1136/heart.88.2.193 · 6.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The most common clinical manifestations of fibromuscular dysplasia (FMD) are hypertension due to renal artery involvement and transient ischemic attack or stroke due to carotid or vertebral artery involvement. Patients with renal artery FMD and hypertension should undergo primary angioplasty with the goal of curing the hypertension. If the blood pressure fails to normalize following angioplasty, the physician should institute antihypertensive medications according to the recommendations of the Joint National Committee on the Prevention, Detection, and Treatment of High Blood Pressure VII. In patients with cerebrovascular FMD, antiplatelet agents represent the cornerstone of therapy. Percutaneous angioplasty has emerged as the preferred treatment for symptomatic cerebrovascular FMD.
    Current Treatment Options in Cardiovascular Medicine 03/2005; 7(2):159-169. DOI:10.1007/s11936-005-0017-z
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Palmaz Genesis Peripheral Stainless Steel Balloon Expandable Stent in Renal Artery Treatment (GREAT) Trial was designed to assess the safety and performance of a low-profile stent for the treatment of obstructive renal artery disease by looking at 6-month renal artery patency uniformly analyzed by a Core Lab. Fifty-two consecutive patients (mean age, 63.7 years) were successfully treated with the Palmaz Genesis Peripheral Stent (Cordis, Miami, FL) on the Slalom 0.018-inch Delivery System (Cordis Europe N.V., Oosteinde 8, NLO-9301 LJ Roden, The Netherlands) at 11 investigational centers. Patients with severe renal failure and > 8-mm renal artery were excluded. Primary endpoint was angiographic determination of in-stent percent diameter stenosis at 6 months. Fifty-one patients were treated with one stent, one patient was treated with two stents to cover the complete lesion. Mean percentage diameter stenosis before renal angioplasty was 68.2% +/- 12.0%. No stent implantation failure, displacement, need for additional stent implantation, or procedural complication was observed. Six-month angiography was performed in 41 of 52 patients (79%) resulting in a mean in-stent percent diameter stenosis or Quantitative Vessel analysis (QVA) at 6 months of 23.9%. The in-stent binary (percent diameter stenosis > 50%) restenosis rate at 6 months was 14.3%. No fatal events occurred up to 6 months after implantation. Major adverse events occurred in five patients: four patients (7.7%) required a revascularization and one patient (1.9%) experienced a cerebrovascular event, which regressed spontaneously. The Palmaz Genesis stent (Cordis) provides good results for renal artery stent placement, with an in-stent binary restenosis rate (percent diameter stenosis > 50%) at 6 months of 14.3% as determined with angiography.
    Journal of Vascular and Interventional Radiology 10/2005; 16(9):1195-202. DOI:10.1097/01.RVI.0000171765.67665.D3 · 2.15 Impact Factor
Show more


Available from